D04.5 identifies carcinoma in situ of the skin located on the trunk, a condition where malignant epithelial cells are present but limited to the epidermis without invading the basement membrane or dermis. This condition is most commonly manifested as Bowen's disease, also known as squamous cell carcinoma (SCC) in situ. On the trunk, these lesions frequently present as well-demarcated, slowly enlarging, erythematous, and scaly plaques that may resemble inflammatory dermatoses like psoriasis or nummular eczema. While technically non-invasive, D04.5 has a documented potential to transform into invasive squamous cell carcinoma, which may then metastasize. Risk factors specific to trunk lesions historically included arsenic exposure, but currently, chronic ultraviolet (UV) radiation and immunosuppression are primary drivers. Diagnosis is confirmed via skin biopsy showing full-thickness epidermal dysplasia with pleomorphic nuclei and mitotic figures, but with a preserved basement membrane.
Explicitly identify the specific anatomical sub-location of the trunk to ensure accuracy within the D04.5 category.
Example: Biopsy of the 3.2 cm erythematous scaly plaque on the right upper back (trunk) confirms Bowen disease, which is carcinoma in situ of the skin of the trunk. This primary lesion is located in a high-friction area and represents a localized neoplastic process without evidence of invasive depth or lymphadenopathy. Treatment plan involves Mohs micrographic surgery given the lesion size and chronic immunosuppression status from the patient's heart transplant.
Billing Focus: Anatomical specificity to the trunk (back, chest, abdomen) and laterality where applicable.
Document the clinical morphology and suspected pathology, specifically mentioning Bowen disease when applicable, as it is the most common form of D04.5.
Example: Patient presents for follow-up of a biopsy-proven carcinoma in situ of the skin of the abdomen (trunk), clinically consistent with Bowen disease. The lesion measures 2.5 cm. Current management includes topical fluorouracil 5 percent cream twice daily for 6 weeks. Patient is at increased risk for future cutaneous malignancies due to history of extensive UV exposure and Fitzpatrick skin type II.
Billing Focus: Matches the ICD-10-CM code for in situ malignancy of the trunk skin.
Describe the lesion's margins and the status of any previous treatments to differentiate between initial presentation and recurrence.
Example: The patient has a recurrent carcinoma in situ of the skin of the chest wall (trunk). The previous excision 2 years ago showed involved margins. Current exam shows a 1.5 cm irregular patch at the surgical scar. Risk factors include previous radiation therapy for lymphoma, which increases the complexity of the current surgical plan and risk of transformation to invasive squamous cell carcinoma.
Billing Focus: Supports medical necessity for more complex surgical interventions if the lesion is recurrent.
Incorporate the size of the lesion and the planned method of eradication, whether surgical, chemical, or cryotherapy.
Example: Plan for cryosurgery of a 0.8 cm carcinoma in situ of the skin of the flank (trunk). This lesion is confined to the epidermis. Patient is also managed for chronic obstructive pulmonary disease and type 2 diabetes, which necessitates careful wound care monitoring post-procedure. The lesion is documented as carcinoma in situ, not actinic keratosis, based on recent pathology.
Billing Focus: Size and method of treatment are critical for selecting the correct CPT code for destruction or excision.
Ensure the documentation clarifies that the lesion is not invasive, which distinguishes D04.5 from C44.5.
Example: Histopathology from the 4.0 cm chest lesion confirms carcinoma in situ of the skin of the trunk (D04.5). There is no evidence of dermal invasion, distinguishing this from an invasive squamous cell carcinoma. The large size of the lesion and its location near the midline requires a complex closure following planned wide local excision.
Billing Focus: Distinguishes 'in situ' (D04.5) from 'malignant' (C44.51x) to prevent over-billing or under-billing.
Typically used for a stable patient being managed with topical agents for D04.5.
D04.5 is considered a malignant lesion for CPT excision selection purposes.
A common method for treating Bowen disease of the trunk when surgery is not preferred.
Necessary to establish the in situ nature of the lesion before committing to more aggressive therapy.
Though primary trunk lesions are often 17313, 17311 is used if the site is considered high risk or recurrent.
Applicable for large-field Bowen disease where topical therapy has failed.
Appropriate when the new patient requires a comprehensive skin exam and counseling regarding multiple neoplastic lesions.
Used when the excision of a D04.5 lesion requires more than a simple one-layer closure.
Efficient treatment for small, early-stage Bowen disease lesions.
Patients with one D04.5 lesion often have multiple areas of concern requiring separate diagnoses.